CA2963639C - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith - Google Patents

Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith Download PDF

Info

Publication number
CA2963639C
CA2963639C CA2963639A CA2963639A CA2963639C CA 2963639 C CA2963639 C CA 2963639C CA 2963639 A CA2963639 A CA 2963639A CA 2963639 A CA2963639 A CA 2963639A CA 2963639 C CA2963639 C CA 2963639C
Authority
CA
Canada
Prior art keywords
purin
chloro
lamino
ylamino
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2963639A
Other languages
English (en)
French (fr)
Other versions
CA2963639A1 (en
Inventor
Matthew Alexander
Sogole Bahmanyar
John Frederick Boylan
Joshua Hansen
Dehua Huang
Robert Hubbard
Brandon Jeffy
Jim Leisten
Mehran Moghaddam
Raj K. Raheja
Heather Raymon
Kimberly Schwarz
Marianne Sloss
Eduardo Torres
Tam Minh Tran
Shuichan Xu
Jingjing Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CA2963639A1 publication Critical patent/CA2963639A1/en
Application granted granted Critical
Publication of CA2963639C publication Critical patent/CA2963639C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2963639A 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith Active CA2963639C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
CA2963639A1 CA2963639A1 (en) 2016-04-14
CA2963639C true CA2963639C (en) 2023-07-04

Family

ID=55632334

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963639A Active CA2963639C (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Country Status (28)

Country Link
US (8) US9512124B2 (cg-RX-API-DMAC7.html)
EP (2) EP3204386B1 (cg-RX-API-DMAC7.html)
JP (4) JP6884701B2 (cg-RX-API-DMAC7.html)
KR (2) KR102504849B1 (cg-RX-API-DMAC7.html)
CN (2) CN107001372B (cg-RX-API-DMAC7.html)
AR (2) AR102171A1 (cg-RX-API-DMAC7.html)
AU (2) AU2015328414B2 (cg-RX-API-DMAC7.html)
CA (1) CA2963639C (cg-RX-API-DMAC7.html)
CL (1) CL2017000820A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003838A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124173T1 (cg-RX-API-DMAC7.html)
DK (1) DK3204386T3 (cg-RX-API-DMAC7.html)
EA (1) EA201790779A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17026210A (cg-RX-API-DMAC7.html)
ES (2) ES2980464T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210656T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054694T2 (cg-RX-API-DMAC7.html)
IL (2) IL251566B (cg-RX-API-DMAC7.html)
LT (1) LT3204386T (cg-RX-API-DMAC7.html)
MX (2) MX388321B (cg-RX-API-DMAC7.html)
PL (1) PL3204386T3 (cg-RX-API-DMAC7.html)
PT (1) PT3204386T (cg-RX-API-DMAC7.html)
RS (1) RS61884B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202009598VA (cg-RX-API-DMAC7.html)
SI (1) SI3204386T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100302T1 (cg-RX-API-DMAC7.html)
TW (1) TW201629063A (cg-RX-API-DMAC7.html)
WO (1) WO2016057370A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2980464T3 (es) * 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR102630010B1 (ko) 2015-03-18 2024-01-25 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
CA3208587A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
WO2017173218A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
BR112018070163A2 (pt) * 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
CN109563095B (zh) * 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
KR20200062270A (ko) 2017-10-04 2020-06-03 셀진 코포레이션 시스-4-[2-{[(3s,4r)-3-플루오로옥산-4-일]아미노}-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸시클로헥산-1-카르복스아미드의 조성물 및 이용 방법
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
RU2496780C2 (ru) 2006-10-27 2013-10-27 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Твердые формы
WO2009130342A1 (es) 2008-04-23 2009-10-29 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2980464T3 (es) 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
WO2017173218A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Also Published As

Publication number Publication date
WO2016057370A1 (en) 2016-04-14
NZ767954A (en) 2024-02-23
JP6884701B2 (ja) 2021-06-09
KR20170063740A (ko) 2017-06-08
US10940152B2 (en) 2021-03-09
JP2022033858A (ja) 2022-03-02
AR102171A1 (es) 2017-02-08
US20190336507A1 (en) 2019-11-07
AU2015328414B2 (en) 2020-03-19
EP3204386A4 (en) 2018-04-18
KR102504849B1 (ko) 2023-03-02
US10646493B2 (en) 2020-05-12
SG11201702759XA (en) 2017-05-30
EP3204386B1 (en) 2021-03-03
JP2017530199A (ja) 2017-10-12
US20160096841A1 (en) 2016-04-07
IL277069B (en) 2022-05-01
KR20230035424A (ko) 2023-03-13
SI3204386T1 (sl) 2021-08-31
CN107001372A (zh) 2017-08-01
IL277069A (en) 2020-10-29
JP2023027269A (ja) 2023-03-01
CL2017000820A1 (es) 2017-12-15
EP3204386A1 (en) 2017-08-16
MX2017004600A (es) 2017-06-30
US11590139B2 (en) 2023-02-28
ES2871142T3 (es) 2021-10-28
JP7196270B2 (ja) 2022-12-26
US9737541B2 (en) 2017-08-22
BR112017006998A2 (pt) 2018-01-16
CA2963639A1 (en) 2016-04-14
NZ730753A (en) 2024-02-23
US9512124B2 (en) 2016-12-06
US20170042902A1 (en) 2017-02-16
US10398700B2 (en) 2019-09-03
US20170296546A1 (en) 2017-10-19
CN107001372B (zh) 2021-04-27
CY1124173T1 (el) 2022-05-27
HRP20210656T1 (hr) 2021-07-23
EA201790779A1 (ru) 2017-09-29
US20230158035A1 (en) 2023-05-25
HUE054694T2 (hu) 2021-09-28
CO2017003838A2 (es) 2017-07-11
CN113248506A (zh) 2021-08-13
JP2020033352A (ja) 2020-03-05
AU2020201486A1 (en) 2020-03-19
ES2980464T3 (es) 2024-10-01
EP3822274B1 (en) 2024-03-06
US20190091230A1 (en) 2019-03-28
DK3204386T3 (da) 2021-05-25
JP6987823B2 (ja) 2022-01-05
ECSP17026210A (es) 2017-05-31
EP3822274A1 (en) 2021-05-19
MX2021014531A (es) 2022-01-06
IL251566A0 (en) 2017-05-29
SG10202009598VA (en) 2020-10-29
US20200237768A1 (en) 2020-07-30
US10149849B2 (en) 2018-12-11
AU2020201486B2 (en) 2021-07-08
LT3204386T (lt) 2021-07-12
SMT202100302T1 (it) 2021-07-12
PT3204386T (pt) 2021-05-31
AU2015328414A1 (en) 2017-04-27
TW201629063A (zh) 2016-08-16
MX388321B (es) 2025-03-19
RS61884B1 (sr) 2021-06-30
US20210128565A1 (en) 2021-05-06
PL3204386T3 (pl) 2021-09-20
AR128748A2 (es) 2024-06-12
IL251566B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
CA2963639C (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CA2829264C (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CA2934061A1 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
AU2016369652B2 (en) Alkyl dihydroquinoline sulfonamide compounds
WO2018017896A1 (en) Pyridine sulfonamides
CA3228265A1 (en) Methods of treating migraine with mnk inhibitors
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928

EEER Examination request

Effective date: 20200928